瞄准未来：卵巢癌靶向治疗的新进展

doi:10.3969/j.issn.1006-5725.2024.14.001

Abstract

Abstract:

Ovarian cancer represents a significant threat to women's health globally， with particularly high recurrence and mortality rates in China's context of gynecological malignancies. The effectiveness of traditional therapeutic approaches for advanced and recurrent ovarian cancer remains quite limited. However， recent studies have highlighted the substantial success of targeted therapies in managing ovarian cancer. This paper delves into both national and international research on ovarian cancer's targeted treatments， examining their mechanisms， applications， current landscape， and the challenges they face. It aims to offer innovative perspectives and directions for ovarian cancer treatment.

Key words: ovarian cancer, targeted rherapy, PARP Inhibitors, ADCs, research progress

CLC Number:

R737.33

Shan′gao HUANG,Yueling WU,Ying. ZHANG. Aiming for the future： The latest advances in targeted therapy for ovarian cancer[J]. The Journal of Practical Medicine, 2024, 40(14): 1901-1907.

Figures/Tables 1

References 31

1	LHOTOVA K， STOLAROVA L， ZEMANKOVA P， et al. Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer ［J］. Cancers （Basel）， 2020，12（4）：956. doi:10.3390/cancers12040956 doi: 10.3390/cancers12040956
2	WANG Y， WANG Z， ZHANG Z， et al. Burden of ovarian cancer in China from 1990 to 2030： A systematic analysis and comparison with the global level ［J］.Front Public Health， 2023，11：1136596. doi:10.3389/fpubh.2023.1136596 doi: 10.3389/fpubh.2023.1136596
3	BEREK J S， RENZ M， KEHOE S， et al. Cancer of the ovary， fallopian tube， and peritoneum： 2021 update ［J］.Int J Gynaecol Obstet， 2021，155（Suppl 1）：61-85. doi:10.1002/ijgo.13878 doi: 10.1002/ijgo.13878
4	LI S， TOPATANA W， JUENGPANICH S， et al. Development of synthetic lethality in cancer： molecular and cellular classification ［J］. Signal Transduct Target Ther， 2020，5（1）：241. doi:10.1038/s41392-020-00358-6 doi: 10.1038/s41392-020-00358-6
5	BANERJEE S， MOORE K N， COLOMBO N， et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation （SOLO1/GOG 3004）： 5-year follow-up of a randomised， double-blind， placebo-controlled， phase 3 trial ［J］. Lancet Oncol， 2021，22（12）：1721-1731. doi:10.1016/s1470-2045(21)00531-3 doi: 10.1016/s1470-2045(21)00531-3
6	LEE J， LEE Y， PARK J， et al. Major clinical research advances in gynecologic cancer in 2022： highlight on late-line PARP inhibitor withdrawal in ovarian cancer， the impact of ARIEL-4， and SOLO-3 ［J］. J Gynecol Oncol， 2023，34（2）：e51. doi:10.3802/jgo.2023.34.e51 doi: 10.3802/jgo.2023.34.e51
7	VENEZIANI A C， SCOTT C， WAKEFIELD M J， et al. Fighting resistance： post-PARP inhibitor treatment strategies in ovarian cancer ［J］. Ther Adv Med Oncol， 2023，15：2602380. doi:10.1177/17588359231157644 doi: 10.1177/17588359231157644
8	MAIORANO M F P， MAIORANO B A， BIANCOFIORE A， et al. Niraparib and Advanced Ovarian Cancer： A Beacon in the Non-BRCA Mutated Setting ［J］. Pharmaceuticals （Basel）， 2023，16（9）：1261. doi:10.3390/ph16091261 doi: 10.3390/ph16091261
9	DISILVESTRO P， BANERJEE S， COLOMBO N， et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation： The SOLO1/GOG 3004 Trial ［J］. J Clin Oncol， 2023，41（3）：609-617. doi:10.1200/jco.22.01549 doi: 10.1200/jco.22.01549
10	AUGUSTIN H G， KOH G Y. Antiangiogenesis： Vessel Regression， Vessel Normalization， or Both？［J］. Cancer Res， 2022，82（1）：15-17. doi:10.1158/0008-5472.can-21-3515 doi: 10.1158/0008-5472.can-21-3515
11	ARORA S， BALASUBRAMANIAM S， ZHANG H， et al. FDA Approval Summary： Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer ［J］. Oncologist， 2021，26（1）：e164-e172. doi:10.1002/onco.13551 doi: 10.1002/onco.13551
12	MARCHETTI C， MUZII L， ROMITO A， et al. First-line treatment of women with advanced ovarian cancer： focus on bevacizumab ［J］. Onco Targets Ther， 2019，12：1095-1103. doi:10.2147/ott.s155425 doi: 10.2147/ott.s155425
13	BURGER R A， SILL M W， MONK B J， et al. Phase Ⅱ trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer： a Gynecologic Oncology Group Study ［J］. J Clin Oncol， 2007，25（33）：5165-5171. doi:10.1200/jco.2007.11.5345 doi: 10.1200/jco.2007.11.5345
14	AGHAJANIAN C， BLANK S V， GOFF B A， et al. OCEANS： a randomized， double-blind， placebo-controlled phase Ⅲ trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian， primary peritoneal， or fallopian tube cancer［J］. J Clin Oncol， 2012，30（17）：2039-2045. doi:10.1200/jco.2012.42.0505 doi: 10.1200/jco.2012.42.0505
15	HAUNSCHILD C E， TEWARI K S. Bevacizumab use in the frontline， maintenance and recurrent settings for ovarian cancer ［J］. Future Oncol， 2020，16（7）：225-246. doi:10.2217/fon-2019-0042 doi: 10.2217/fon-2019-0042
16	HETTLE R， MCCREA C， LEE C K， et al. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer ［J］. Ther Adv Med Oncol， 2021，13：17505625. doi:10.1177/17588359211049639 doi: 10.1177/17588359211049639
17	MIRZA M R， ÅVALL LUNDQVIST E， BIRRER M J， et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer （NSGO-AVANOVA2/ENGOT-ov24）： a randomised， phase 2， superiority trial ［J］. Lancet Oncol， 2019，20（10）：1409-1419. doi:10.1016/s1470-2045(19)30515-7 doi: 10.1016/s1470-2045(19)30515-7
18	MERIC-BERNSTAM F， MAKKER V， OAKNIN A， et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors： Primary Results From the DESTINY-PanTumor02 Phase Ⅱ Trial ［J］. J Clin Oncol， 2024，42（1）：47-58. doi:10.1200/jco.23.02005 doi: 10.1200/jco.23.02005
19	HEO Y. Mirvetuximab Soravtansine： First Approval ［J］. Drugs， 2023，83（3）：265-273. doi:10.1007/s40265-023-01834-3 doi: 10.1007/s40265-023-01834-3
20	MOORE K N， OZA A M， COLOMBO N， et al. Phase Ⅲ， randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer： primary analysis of FORWARD I ［J］. Ann Oncol， 2021，32（6）：757-765. doi:10.1016/j.annonc.2021.02.017 doi: 10.1016/j.annonc.2021.02.017
21	GILBERT L， OAKNIN A， MATULONIS U A， et al. Safety and efficacy of mirvetuximab soravtansine， a folate receptor alpha （FRalpha）-targeting antibody-drug conjugate （ADC）， in combination with bevacizumab in patients with platinum-resistant ovarian cancer ［J］. Gynecol Oncol， 2023，170：241-247. doi:10.1016/j.ygyno.2023.01.020 doi: 10.1016/j.ygyno.2023.01.020
22	MOORE K N， ANGELERGUES A， KONECNY G E， et al. Phase Ⅲ MIRASOL （GOG 3045/ENGOT-ov55） study： Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant， advanced high-grade epithelial ovarian， primary peritoneal， or fallopian tube cancers with high folate receptor-alpha expression ［J］. J Clin Oncol， 2023，41（）：LBA5507. doi:10.1200/jco.2023.41.17_suppl.lba5507 doi: 10.1200/jco.2023.41.17_suppl.lba5507
23	MANZANO A， OCANA A. Antibody-Drug Conjugates： A Promising Novel Therapy for the Treatment of Ovarian Cancer ［J］. Cancers （Basel）， 2020，12（8）：2223. doi:10.3390/cancers12082223 doi: 10.3390/cancers12082223
24	EMBABY A， KUTZERA J， GEENEN J J， et al. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer： A biomarker-enriched phase Ⅱ study ［J］. Gynecol Oncol， 2023，174：239-246. doi:10.1016/j.ygyno.2023.05.063 doi: 10.1016/j.ygyno.2023.05.063
25	ZHANG C， PENG K， LIU Q， et al. Adavosertib and beyond： Biomarkers， drug combination and toxicity of WEE1 inhibitors ［J］. Crit Rev Oncol Hematol， 2023，193：104233. doi:10.1016/j.critrevonc.2023.104233 doi: 10.1016/j.critrevonc.2023.104233
26	BARTOLETTI M， PELIZZARI G， GERRATANA L， et al. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer： A Network Meta-Analysis ［J］. Int J Mol Sci， 2020，21（11）：3805. doi:10.3390/ijms21113805 doi: 10.3390/ijms21113805
27	MAREI H E， CENCIARELLI C， HASAN A. Potential of antibody-drug conjugates （ADCs） for cancer therapy ［J］. Cancer Cell Int， 2022，22（1）：255. doi:10.1186/s12935-022-02679-8 doi: 10.1186/s12935-022-02679-8
28	TONG J T W， HARRIS P W R， BRIMBLE M A， et al. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy ［J］. Molecules， 2021，26（19）：5847. doi:10.3390/molecules26195847 doi: 10.3390/molecules26195847
29	王涛，宋飞雪. 铂耐药卵巢癌的免疫治疗进展［J］. 2021，37（20）：2575-2579. doi:10.3969/j.issn.1006-5725.2021.20.002 doi: 10.3969/j.issn.1006-5725.2021.20.002
30	尹萍，徐寒子，朱晨静. 循环肿瘤DNA在妇科恶性肿瘤中的应用［J］.实用医学杂志， 2023，39（17）：2153-2158. doi:10.3969/j.issn.1006-5725.2023.17.001 doi: 10.3969/j.issn.1006-5725.2023.17.001
31	彭佳欣，张自辉，洪莉. m6A修饰在卵巢癌中的研究进展［J］. 实用医学杂志， 2023，39（12）：1577-1583. doi:10.3969/j.issn.1006-5725.2023.12.020 doi: 10.3969/j.issn.1006-5725.2023.12.020

[1]	Shan GAO,Kun JI,Li ZHAO,Yujia XING,Yandong XIE,Xiqiang CAI. Research progress on esophageal squamous intraepithelial neoplasia [J]. The Journal of Practical Medicine, 2024, 40(3): 432-438.
[2]	Ganggang LU,Shenglong LI,Yongqiang ZHAO,Yunpeng JIA,Yonglin LIANG,Yuanbo. ZHAO. Research progress on the correlation between oxidative stress and ferroptosis in diabetic impotence [J]. The Journal of Practical Medicine, 2024, 40(16): 2229-2235.
[3]	Xin DOU,Changhui HE,Xiao MEI,Haidi PAN,Yuanxin MA,Wei. WANG. Research progress on the intervention of traditional Chinese medicine in IBS⁃D based on the "SCFAs⁃intestinal barrier" pathway [J]. The Journal of Practical Medicine, 2024, 40(15): 2177-2182.
[4]	Haixia YUAN,Xinmin HAN,Tianyi CHEN,Yuchen. SONG. Progress on structural abnormalities in the cerebral cortex in children with attention deficit/hyperactivity disorder [J]. The Journal of Practical Medicine, 2024, 40(10): 1455-1459.
[5]	HE Wanshan , HONG Xiaoshan, CHEN Guanqiao, CHEN Bin, WEN Bin, LIN Yu, WEI Zhifu, LUO Xiping. Screening of gene differential expression of NSUN2 in ovarian cancer cells based on transcriptome sequenc⁃ ing technology [J]. The Journal of Practical Medicine, 2023, 39(9): 1079-1085.
[6]	Yadan CHE,Lixia. LI. Reaserch progress on small molecule anti⁃angiogenic drugs for advanced breast cancer [J]. The Journal of Practical Medicine, 2023, 39(22): 2866-2871.
[7]	Ping YIN,Hanzi XU,Chenjing. ZHU. Application of ctDNA in gynecological malignant cancer [J]. The Journal of Practical Medicine, 2023, 39(17): 2153-2158.
[8]	Lin LIU,Runrong LI,Shipeng. GONG. Efficacy and safety of PEG⁃rhG⁃CSF for preventing neutropenia after chemotherapy with doxorubicin plus carboplatin in epithelial ovarian cancer patients： A retrospective clinical study [J]. The Journal of Practical Medicine, 2023, 39(17): 2236-2240.
[9]	Chongfeng SUN,Ping YANG,Jishuai HOU,Zouyu ZHAO,Panpan. YU. Expression and prognosis of STT3A and STT3B in epithelial ovarian cancer [J]. The Journal of Practical Medicine, 2023, 39(16): 2062-2070.
[10]	Jianxiang CHENG,Wensheng DU,Min WEI,Guanghui. WANG. Expression of LMNB1 in ovarian cancer and its effect on biological behavior of ovarian cancer cells [J]. The Journal of Practical Medicine, 2023, 39(16): 2077-2084.
[11]	PENG Jiaxin, ZHANG Zihui, HONG Li. . Role of m6A modification in ovarian cancer：A review of literature [J]. The Journal of Practical Medicine, 2023, 39(12): 1577-1583.
[12]	LIU Hui, HE Caixian, PENG Jiyong, ZHONG Xi, LIAO Kai, YUAN Yawei, ZHENG Ronghui.. Carotid arterial injuries caused by radiotherapy for nasopharyngeal carcinoma：A review [J]. The Journal of Practical Medicine, 2023, 39(10): 1201-1205.
[13]	JIANG Ping, GUO Zhe, LIANG Dianxun, YANG Xike, FU Xiaoling, LI Heli. Influence of long non ⁃coding RNA XIST on epithelial ⁃mesenchymal transition in ovarian cancer cells by regulating miR⁃340⁃5p [J]. The Journal of Practical Medicine, 2023, 39(1): 41-47.
[14]	LI Yanwei, WANG Bin, MIAO Yulu, LI Xiao⁃ jin, ZHANG Yadong, HAN Juan, ZHUANG Pengwei, ZHANG Yanjun.. Research progress of intestinal barrier dysfunction in sepsis [J]. The Journal of Practical Medicine, 2022, 38(7): 799-803.
[15]	PU Yukang, HUANG Yuqin, LI Wei, LI Mingqun.. Expression and clinical significance of KIF26B in epithelial ovarian cancer based on biological information [J]. The Journal of Practical Medicine, 2022, 38(23): 2919-2926.

Aiming for the future： The latest advances in targeted therapy for ovarian cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 31

Related Articles 15

Recommended Articles

Metrics

Comments